ECP 2019 Final Programme

7 ECP 2019 · Nice Keynote Speakers e Michael Middleton (USA) Dr Middleton is a Radiologist, and Director of Clinical Trials for the Liver Imaging Group at the University of California, San Diego. He is on the NASH CRN (Nonalcoholic Steatohepatitis Clinical Research Network) Steering Committee and the PDFF (proton density fat fraction) and MRE (magnetic resonance elastography) quantitative imaging biomarker committees as part of QIBA (Quantative Imaging Biomarkers Alliance), part of the NIMBLE (Non-Invasive BioMarkers of MetaBolic Liver DiseasE) Imaging Workstream Group, and has been author or co-author of numerous publications in the field. For the last 12 years he has been involved extensively in the implementation, analysis, and quality control of quantitative magnitude MRI-PDFF (magnetic resonance imaging-proton density fat fraction) and MRE liver stiffness imaging exams in 28 drug development clinical trials involving several thousand pharmaceutical industry MR scans obtained at over 300 sites worldwide. This work has enabled a working, practical understanding of how to implement MRI PDFF and MRE liver stiffness estimation sequences on a wide variety of different styles and models of scanners from most of the major MRI scanner manufacturers, and to identify and correct scanner- and sequence-specific problems. It has also provided invaluable multi-center, multi-scanner data on which to develop and test quantitative metrics of adequacy for MRI-PDFF and MRE liver stiffness biomarkers, and to compare imaging assessments of hepatic steatosis and fibrosis with pathology.

RkJQdWJsaXNoZXIy Mzg2Mjgy